Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Pneumosil 2+1 Schedule in Healthy Infants
NCT03896477Phase 3Completed
- Sponsor
- PATH
- Start
- Jul 2019
- Primary completion
- Dec 2020
- Modality
- Split/Subunit Vaccines
- Countries
- 1
01
Overview
Phase 3, randomised, double-blind trial of SIILPCV10 in Pneumococcal pneumonia (PP) (3 arms), sponsored by PATH. Primary endpoints: Geometric Mean Concentration of Serotype-specific IgG Antibodies, Number of Participants With Solicited Local and Systemic Adverse Events and 1 more. Started Jul 2019; status: completed.
02
Drugs
SIILPCV10
03
Conditions
Pneumococcal pneumonia (PP)
Beyond the preview
Go deeper on NCT03896477.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03896477.